Insulet is trading 4.05% down at $149.79 as healthcare shares face pressure amid post-election policy uncertainty.
- The healthcare sector is down 1.48%; sector pressure is broadly attributed to uncertainty around drug-price negotiations and other regulatory changes.
- Insulet’s November 4 results included $842 million in revenue and raised full-year guidance, which do not clearly explain the current drop. On November 6, UBS maintained Neutral and raised its price target from $150 to $171.